General-purpose VLMs remain unreliable for biomedical research because valid answers in scientific papers depend on evidence split across figures, tables, charts, captions, and referring text. Existing post-training pipelines are bottlenecked by costly expert annotation and by synthetic data that drops this evidence structure. We present Ryze, a fully automated system that converts raw biomedical papers into an evidence-enriched training set and a domain-specialized VLM. Ryze synthesizes QA pairs with complete supporting evidence (visual element, caption, extracted structure, and referring paragraphs), reduces layout and OCR errors via chart/table-aware extraction and LLM-based cleansing, and applies a progress-gated post-training strategy combining supervised fine-tuning with reinforcement learning. Starting from Qwen3-VL-8B, Ryze produces BioVLM-8B at under USD 200, achieving 48.0% weighted accuracy on LAB-Bench, outperforming the base model by +12.6 percentage points (pp) and surpassing GPT-5.2 by +3.8 pp. We release Ryze as open source together with the trained BioVLM-8B model.
Assessing whether an article supports an assertion is essential for hallucination detection and claim verification. While large language models (LLMs) have the potential to automate this task, achieving strong performance requires frontier models such as GPT-5 that are prohibitively expensive to deploy at scale. To efficiently perform biomedical evidence attribution, we present Med-V1, a family of small language models with only three billion parameters. Trained on high-quality synthetic data newly developed in this study, Med-V1 substantially outperforms (+27.0% to +71.3%) its base models on five biomedical benchmarks unified into a verification format. Despite its smaller size, Med-V1 performs comparably to frontier LLMs such as GPT-5, along with high-quality explanations for its predictions. We use Med-V1 to conduct a first-of-its-kind use case study that quantifies hallucinations in LLM-generated answers under different citation instructions. Results show that the format instruction strongly affects citation validity and hallucination, with GPT-5 generating more claims but exhibiting hallucination rates similar to GPT-4o. Additionally, we present a second use case showing that Med-V1 can automatically identify high-stakes evidence misattributions in clinical practice guidelines, revealing potentially negative public health impacts that are otherwise challenging to identify at scale. Overall, Med-V1 provides an efficient and accurate lightweight alternative to frontier LLMs for practical, real-world biomedical evidence attribution. Med-V1 is available at https://github.com/NLM-DIR/Med-V1.
Pretrained biomedical vision-language models (VLMs) such as BioMedCLIP perform well on average but often degrade on challenging modalities where inter-class margins are small and acquisition-specific variations are pronounced, especially under few-shot supervision and when modality priors differ from pretraining corpora substantially. We propose BioVLM, a prompt-learning framework that improves cross-domain generalization without extensive backbone fine-tuning. BioVLM learns a diverse prompt bank and introduces dynamic prompt selection: for each input, it selects the most discriminative prompts via a low-entropy criterion on the predictive distribution, effectively coupling sparse few-shot evidence with rich LLM semantic priors. To strengthen this coupling, we distill high-confidence LLM-derived attributes and enforce robust knowledge transfer through strong/weak augmentation consistency. At test time, BioVLM adapts by choosing modality-appropriate prompts, enabling transfer to unseen categories and domains, while keeping training lightweight and inference efficient. On 11 MedMNIST+ 2D datasets, BioVLM achieves new state of the art across three distinct generalization settings. Codes are available at https://github.com/mainaksingha01/BioVLM.
Large Language Models such as GPT-4o and GPT-5 achieve strong zero-shot performance on biomedical claim verification, but cost and opacity limit scalable use. We fine-tune three small LLMs: Phi-3-mini (3.8B), Qwen2.5-3B, and Mistral-7B, via QLoRA on SciFact and HealthVer, providing the first study of QLoRA models against GPT-4o and fine-tuned BioLinkBERT encoders. Mistral-7B QLoRA surpasses both GPT-4o and GPT-5 (up to 12% F1 gain) at a fractional cost using just 1,008 training examples. We conduct extensive in-domain and cross-domain evaluation: models trained on SciFact tested on HealthVer and vice versa, at matched sizes to isolate dataset structure from data quantity. We identify a previously unreported structural artifact in SciFact that inflates in-domain scores, and show through bidirectional out-of-domain evaluation that training on structurally sound data enables robust cross-domain transfer. We plan to release all code and adapter checkpoints.